Addition of Sorafenib to carboplatin/paclitaxel chemotherapy adds no benefit in lung cancer « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Addition of Sorafenib to carboplatin/paclitaxel chemotherapy adds no benefit in lung cancer

Posted on April 26, 2008 by crimsoncanary

No benefit was observed in a trial evaluating the benefit of adding sorafenib (Nexavar) to a carboplatin/paclitaxel combination chemotherapy in lung cancer patients. The trial has been stopped after analysis of interim results. Data was presented by Prof. Giorgio Scagliotti from the University of Torino.

Filed under: kinase | Tagged: bayer, multikinase, Nexavar, onyx, sorafenib

« Vargatef demonstrates efficacy in patients with advanced, relapsed NSCLC VEGF Trap shows beneficial results in AMD »

Leave a Reply